Actuate Therapeutics (ACTU) Stock: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$0.71
-0.02 (-3.06%)
▼
5d:
-11.61%
30d:
-56.88%
90d:
-53.35%
WAIT
LOW Confidence
Analysis Updated: Sep 29, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACTU is down 11.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACTU is down 11.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $0.71, which is considered oversold relative to its 30-day fair value range of $0.83 to $1.50.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $0.60, while resistance sits at $1.05. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.68 (+1487.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $0.60, while resistance sits at $1.05. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.68 (+1487.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.83 -
$1.50
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (58/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 1487.0% below Wall St target ($11.68)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.60
Resistance Level
$1.05
Current Trend
Strong Downtrend
Technical data as of
Sep 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.11
Wall Street Target
$11.68
(+1487.0%)
Share & Embed Analysis
Last updated: September 29, 2026 3:04 PM ET
Data refreshes hourly during market hours. Next update: 4:04 PM
Data refreshes hourly during market hours. Next update: 4:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 53 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 60 BUY |
